Literature DB >> 19837606

Pulmonary hypertension in heart transplantation: discrepant prognostic impact of pre-operative compared with 1-year post-operative right heart hemodynamics.

Einar Gude1, Svein Simonsen, Odd R Geiran, Arnt E Fiane, Lars Gullestad, Satish Arora, Anne Relbo, Arne K Andreassen.   

Abstract

BACKGROUND: The prognostic impact of pulmonary hypertension (PH) before and after heart transplantation (HTx) is debated. We investigated: (i) the significance of pre-operative reversible PH on post-operative survival; (ii) the value of recatheterization while on the waiting list; (iii) the evolution of right heart hemodynamics (RHH) after HTx; and (iv) the prognostic impact of PH at 1 year after HTx.
METHODS: We reviewed the records of 500 HTx recipients transplanted between 1983 and 2007. Pre-operatively, a non-PH group (Group 1, n = 365) fulfilled directly our RHH criteria for HTx, while a PH group (Group 2, n = 135) was accepted after reversibility of PH by acute vasodilatory testing. Recatheterization was performed every third month while on the waiting list and repeatedly after transplantation.
RESULTS: With a follow-up of 6.8 +/- 5.1 years and a 50% survival rate of 12.1 +/- 5.4 years, our main findings were as follows: (i) Patients with reversible PH on vasodilatory testing had a survival rate similar to that of patients without PH (11.7 +/- 0.8 vs 12.1 +/- 0.5 years, p = 0.80). (ii) Pre-operative recatheterization was of limited value as RHH remained stable. Five percent of patients died while on the waiting list and 2 improved clinically and were removed. (iii) Mean pulmonary artery pressure (MAP) was reduced from 28 +/- 9 and 40 +/- 8 mm Hg pre-operatively to 21 +/- 7 and 24 +/- 6 mm Hg after 2 weeks and 16 +/- 7 and 18 +/- 8 mm Hg at 3 years in Groups 1 and 2, respectively. (iv) Recipients with MAP >20 mm Hg at 1 year post-HTx had significantly lower survival than those with MAP <or=20 mm Hg (11.5 +/- 0.7 vs 15.6 +/- 0.6 years, p < 0.001).
CONCLUSIONS: Elevated pulmonary pressure 1 year after HTx provides significant prognostic information regarding long-term outcome, whereas pre-operative reversible PH in this group does not influence survival.

Entities:  

Mesh:

Year:  2009        PMID: 19837606     DOI: 10.1016/j.healun.2009.08.021

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  6 in total

1.  Right Ventricular Dysfunction and Its Contribution to Morbidity and Mortality in Left Ventricular Heart Failure.

Authors:  Amresh Raina; Talha Meeran
Journal:  Curr Heart Fail Rep       Date:  2018-04

2.  International Society of Heart and Lung Transplantation position statement on the role of right heart catheterization in the management of heart transplant recipients.

Authors:  Hoong Sern Lim; Eileen Hsich; Keyur B Shah
Journal:  J Heart Lung Transplant       Date:  2018-12-21       Impact factor: 10.247

3.  Hemodynamic Characteristics Including Pulmonary Hypertension at Rest and During Exercise Before and After Heart Transplantation.

Authors:  Jakob Lundgren; Göran Rådegran
Journal:  J Am Heart Assoc       Date:  2015-07-21       Impact factor: 5.501

4.  Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients.

Authors:  Niklas Bergh; Einar Gude; Sven-Erik Bartfay; Arne K Andreassen; Satish Arora; Pia Dahlberg; Göran Dellgren; Lars Gullestad; Finn Gustafsson; Kristjan Karason; Göran Rådegran; Entela Bollano; Bert Andersson
Journal:  ESC Heart Fail       Date:  2020-02-14

5.  Early post-transplant elevated pulmonary artery pressure predicts adverse outcome in cardiac recipients.

Authors:  Entela Bollano; Bert Andersson; Clara Hjalmarsson; Göran Dellgren; Bledar Daka; Kristjan Karason
Journal:  Int J Cardiol Heart Vasc       Date:  2019-11-19

6.  Elevated pre-transplant pulmonary vascular resistance is associated with early post-transplant atrial fibrillation and mortality.

Authors:  Rasmus Rivinius; Matthias Helmschrott; Arjang Ruhparwar; Bastian Schmack; Fabrice F Darche; Dierk Thomas; Tom Bruckner; Andreas O Doesch; Hugo A Katus; Philipp Ehlermann
Journal:  ESC Heart Fail       Date:  2020-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.